The hottest Biotechnology Substack posts right now

And their main takeaways

RL Environments and RL for Science: Data Foundries and Multi-Agent Architectures

SemiAnalysis • 15456 implied HN points • 06 Jan 26

🕹 Technology Biotechnology

Scaling reinforcement learning (post‑training) is the main engine of recent capability and utility gains, with labs pouring compute into RL and using broad real‑world evals like GDPval to measure progress.
Building RL environments and datasets is a large, specialized industry — firms clone UIs, create coding and software gyms, and hire domain experts to write tasks and rubrics, spawning many vendors and "RL as a service" offerings.
Applying RL to science and biology requires closed‑loop physical experiments and robotics, faces long costly rollouts and sparse rewards, and will push models and labs toward specialized, non‑commodified solutions.

How to Design Antibodies

Asimov Press • 754 implied HN points • 11 Mar 26

🔬 Science Biotechnology

AI models now let researchers design antibody binders on the computer, greatly reducing the experimental search effort needed to find promising candidates.
There is a practical five-step pipeline — pick a target, prepare or predict its structure, run design tools, filter candidates, and validate in the lab — which uses public tools but typically costs thousands of dollars.
Design success is highly target-dependent and improving affinity, specificity, and drug-like properties remains difficult and costly, but AI makes it realistic to engineer more complex, multi-property binders going forward.

The Quest for Oral GLP-1s

Asimov Press • 303 implied HN points • 16 Mar 26

🔬 Science Biotechnology

People overwhelmingly prefer a once‑daily pill, but peptide drugs are ruined by stomach acid and enzymes and are poorly absorbed, so oral GLP‑1s have very low bioavailability and require huge doses that make them expensive.
Scientists solved injectables by changing the peptide and adding a fatty tail so the drug resists breakdown and sticks to albumin, which gives long lasting, effective once‑weekly shots that oral versions still struggle to match.
A promising shortcut is to engineer edible microbes like spirulina to produce and hide GLP‑1 inside cell walls, which could protect the peptide and slash purification costs to make affordable oral pills — though safety, regulation, and public acceptance remain hurdles.

How Φ80 Infiltrates Research Labs

Asimov Press • 393 implied HN points • 13 Mar 26

🔬 Science Biotechnology

Φ80 quietly infects lab E. coli by integrating into bacterial genomes and replicating slowly, so cultures often look healthy while the phage accumulates and can sporadically cause cell lysis.
P1-transduction, a routine method for moving genes, can unintentionally ferry Φ80 between strains because P1 infection triggers Φ80 replication, turning researchers into unwitting dispersers.
Detecting and stopping Φ80 is hard because targeted or short-read sequencing usually misses prophages and researchers have little incentive to screen; adopting long-read whole-genome sequencing and greater awareness would make infections easier to spot and prevent.

A Visual Guide to DNA Sequencing

Asimov Press • 851 implied HN points • 26 Feb 26

🔬 Science Biotechnology

DNA sequencing has moved from slow, radioactive lab work to fast, automated machines, causing sequencing costs and turnaround times to fall dramatically.
Different technologies make trade-offs: some (like Illumina) give very accurate short reads, others (like PacBio and nanopore) produce long reads useful for repetitive or complex regions, and nanopore adds portability and real-time reading.
These advances have revolutionized biology and medicine by enabling large-scale genome projects, clinical genetic testing, ancient DNA and metagenomics studies, and ongoing efforts to make whole-genome sequencing even cheaper and more widely available.

Get a weekly roundup of the best Substack posts, by hacker news affinity:

Think Stabilized Spike is Bad? Meet Replicon mRNA Vaccines. They are So Bad, We Predict FDA Will Posture for Public Trust on These.

Popular Rationalism • 1069 implied HN points • 03 Oct 24

🏥 Health Politics Biotechnology

Replicon mRNA vaccines have the ability to replicate inside the body, which could lead to unknown risks and side effects. This uncontrolled replication raises concerns about overstimulating the immune system or causing mutations.
Protests in Japan highlight public fear and skepticism surrounding self-replicating vaccines. Many people are worried about the lack of long-term safety data and want more transparency from health officials.
How Japan handles this new vaccine could influence other countries' decisions. Regulatory bodies worldwide need to balance innovation with public safety and trust to avoid backlash and promote acceptance.

Chinese Peptides

ChinaTalk • 607 implied HN points • 20 Feb 26

🔬 Science Biotechnology

Chinese factories and online sellers are mass-producing and exporting a wide range of peptides — from approved drugs to experimental research chemicals — at far lower prices than brand-name medicines. They advertise on social apps and ship directly to foreign customers with fast turnaround and bulk incentives.
Many popular peptides lack robust human trials and can contain hard-to-detect impurities, so injectable dosing and sterility carry real health risks. Regulatory enforcement is murky: sellers use “research use only” labels to dodge oversight and FDA actions have varied with political leadership.
Demand is driven by biohackers, athletes, and people chasing weight loss or faster healing, and injections have become socially normalized after drugs like Ozempic. That demand meets China’s large-scale peptide manufacturing capacity, creating a booming gray market that outpaces formal clinical research.

Countable Labs

ASeq Newsletter • 14 implied HN points • 19 Mar 26

🔬 Science Biotechnology

Countable Labs is building a novel PCR instrument that acts like digital PCR but runs inside a single tube.
Their method seems to isolate individual molecules in a gel, amplify them, and image the fluorescence directly in the tube to enable multiplexed detection.
Public details are limited, so people are looking through patents to understand the technical specifics.

Signal Biosciences

ASeq Newsletter • 21 implied HN points • 17 Mar 26

🔬 Science Biotechnology

They’re building a high-plex PCR approach that runs on standard qPCR and dPCR machines, already showing up to 15 targets in dPCR and a 7‑target qPCR prototype, with aims of roughly 50 and 40 targets respectively.
The key idea is to move fluorescent signal generation out of the genomic amplification and into a parallel isothermal secondary reaction; probe cleavage during PCR produces a cleaved tail that triggers separate signal‑generating chemistries, effectively acting like a barcode.
By decoupling signal chemistry from amplification and pooling fluorophores separately, the method could let developers multiplex many targets in a single reaction without needing specialized instrumentation.

Scent, In Silico

Asimov Press • 432 implied HN points • 16 Feb 26

🔬 Science Biotechnology

Smell is an ancient, highly combinatorial sense driven by hundreds of receptor types, so odors come from complex mixtures and are inherently subjective.
New computational tools like graph neural networks create odor embeddings that map molecules into a perceptual space, letting machines predict smells and design novel odorants.
Digitizing scent promises faster fragrance discovery, diagnostics, safer repellents, and more sustainable synthetic alternatives, while also raising questions about authenticity and how we value natural versus machine-made ingredients.

Ideas for Biotechnology BBNs

FreakTakes • 26 implied HN points • 13 Mar 26

🔬 Science Biotechnology

Flowers by Design: engineer new flower traits across many species to make beautiful, bespoke plants and to uncover general principles of plant development that can translate to food crops.
Biosensor for Anything: build a platform of protein or cell-based sensors plus large datasets and predictive models so we can cheaply and reliably detect many molecules and signals in real-world samples.
Proteins for Pennies: develop a fast, low-cost protein fabricator or "printer" to make any protein for pennies, cutting testing costs and enabling cheaper therapeutics and faster AI-driven design.

Sarmal - FLASH Sequencing!

ASeq Newsletter • 14 implied HN points • 18 Mar 26

🔬 Science Biotechnology

Sarmal is a new company working on DNA sequencing and is pitching a technology called FLASH.
FLASH stands for Fluorescence Activation by Serial Hybridization and is described as involving a polymerase, but the explanation and figure are unclear.
There is a patent for the technology, and deeper details are gated behind a paid subscription paywall.

Weekly Dose of Optimism #181

Not Boring by Packy McCormick • 189 implied HN points • 20 Feb 26

🔬 Science Biotechnology

Heron Power raised $140M to mass-produce modular, software-defined solid-state transformers that use wide-bandgap semiconductors, can handle DC (so some customers can skip inverters), and aim to modernize and shorten supply bottlenecks in the grid.
A new nasal vaccine protected animals against many respiratory viruses, bacteria, and allergens, suggesting a future seasonal spray or rapid pandemic stopgap; human trials are next to check how long protection lasts and whether it’s safe.
David Silver secured $1B to build AI that learns from its own experience, pushing toward an "Era of Experience" where agents improve by interacting with environments rather than just imitating static data.

High-Throughput Chemistry and Engineering with Kadi Saar

Lever • 19 implied HN points • 24 Oct 24

🔬 Science Biotechnology

Kadi Saar has an impressive background in both chemistry and engineering. She excelled in academics and sports, even winning a talent show in mental arithmetic.
Her research focuses on combining high-throughput structural biology with computational chemistry to help develop new drugs. She has shown that analyzing diverse ligand structures can lead to better drug design.
Kadi emphasizes the importance of enjoying the people you work with when choosing projects. Collaborating with good people makes the journey more fulfilling.

Making the Vortex Mixer

Asimov Press • 245 implied HN points • 12 Feb 26

🔬 Science Biotechnology

A simple motorized device called the vortex mixer uses a rubber cup and tight orbital motion to create a vortex that quickly mixes liquids in tubes and small vessels.
The inventors combined technical skill and business savvy to prototype, patent, and commercialize the mixer, then improved it with features like touch activation, speed control, and multi-tube heads.
Vortex mixers made mixing faster, cleaner, and less prone to contamination, becoming a ubiquitous and essential tool in modern biology labs.

Future Of Protein Sequencing

ASeq Newsletter • 29 implied HN points • 11 Mar 26

🔬 Science Biotechnology

Protein sequencing is much harder than DNA sequencing and has fewer broad, foundational applications, making commercial success expensive and difficult.
Without big academic champions and large research projects to drive adoption, companies are forced into niche revenue paths that pull development away from a general-purpose sequencing platform.
There are realistic niche opportunities like biopharma QA/QC and sensitive biomarker detection, but turning protein sequencing into a widely used tool will require sustained funding, risk tolerance, and strong research adopters.

Roche Axelios - My Current Understanding

ASeq Newsletter • 36 implied HN points • 07 Mar 26

🔬 Science Biotechnology

Roche’s Axelios can deliver genomes far cheaper than competitors — the headline is $150/genome, but a near‑Illumina quality simplex 30x genome may be around $30, with duplex offered for higher accuracy.
Initial 19‑hour prep times looked concerning, but an SBX‑Fast workflow suggests similar throughput with about a 3.5‑hour prep; final workflows (especially for simplex) aren’t public and prep time could still affect margins.
The system uses small disposable sensor chips that Roche claims can be reused (~20×), so chip cost likely only adds a modest amount (probably under ~$100) to each run rather than being a major cost driver.

BGI Nanopore Peptide Profiling

ASeq Newsletter • 21 implied HN points • 10 Mar 26

🔬 Science Biotechnology

BGI demonstrated a scaled-up method for classifying peptides with nanopores, showing the approach works beyond small proofs of concept.
They attach DNA handles to peptide ends so peptides can be threaded and paced through a nanopore using existing DNA sequencing control.
The study revealed more technical detail about BGI’s nanopore platform, indicating it could be adapted for larger-scale protein or peptide analysis.

Weekly Dose of Optimism #178

Not Boring by Packy McCormick • 188 implied HN points • 30 Jan 26

🕹 Technology Biotechnology

Brain-computer interfaces have moved from lab demos to real-world use, with implanted devices letting people with paralysis control computers and achieve information transfer rates rivaling a mouse.
Biotech is making bold strides: a three-drug combo eliminated pancreatic tumors in mice, and the first human trial of partial cellular reprogramming to reverse age-related damage has begun in the eye.
AI is unlocking new scientific and creative frontiers—models like AlphaGenome can read regulatory DNA to predict variant effects, while Project Genie can generate playable virtual worlds from simple prompts.

Weekly Dose of Optimism #180

Not Boring by Packy McCormick • 97 implied HN points • 13 Feb 26

🕹 Technology Biotechnology

AI drug design engines can now predict protein-ligand structures and binding strengths far faster and more accurately than older models, turning months of lab search into minutes of computation. If these predictions translate to real-world medicines, we could see many more novel drug candidates enter clinical pipelines, shifting bottlenecks to trials and regulation.
New AI 'deep thinking' modes are able to spend minutes or longer reasoning through hard math, materials, and experimental problems, and can even generate lab-ready protocols for automated equipment. That capability points toward AI-assisted discovery and self-driving labs that amplify human researchers across disciplines.
Researchers found a tiny 45-nucleotide ribozyme that can synthesize its complement and a copy of itself using trinucleotide building blocks, solving a major self-replication puzzle. Its simplicity makes a plausible origin-of-life pathway more likely, linking early replication chemistry to the genetic code we still use today.

Venture Capital Has Lessons for Government and Philanthropy

The Good Science Project • 126 implied HN points • 13 Feb 26

🔬 Science Biotechnology

Government and philanthropic science funding is often bogged down by heavy bureaucracy, rigid reporting, and incentives that favor safe, incremental work over bold, risky ideas.
Venture capital shows useful practices—betting on people not fixed five-year plans, moving fast, tolerating failure, providing networks, and giving investors some personal stake—that could make research funding more effective.
VC isn’t a perfect model because it chases big financial returns and concentrates capital, so reforms should blend VC strengths with public roles like long-term, large-scale, and noncommercial research while creating more diverse, accountable funding institutions.

Illumina Q50, Q70 Reads

ASeq Newsletter • 36 implied HN points • 04 Mar 26

🔬 Science Biotechnology

Illumina has renamed the Constellation product to TruPath.
Illumina unveiled a new 35B flowcell for the NovaSeq X.
They announced Q70 Duplex reads but didn’t share details, and also highlighted progress in spatial genomics, single‑cell, and proteomics.

Open Thread 393

Astral Codex Ten • 3097 implied HN points • 04 Aug 25

🕹 Technology Biotechnology

The Horizon Fellowship is a great opportunity for those interested in AI and biotech. You can apply for a full-time policy position in Washington, and no prior experience is needed.
Inkhaven is a blogging bootcamp for those who want to write more. If you're selected, you'll write a blog post every day for a month, but be ready for some tough love if you miss a day!
There's a cost to attend Inkhaven, but some financial help is available. It's a cool experiment to see if living in a community can boost your motivation to write.

Solving the Electroporation Bottleneck

Asimov Press • 335 implied HN points • 15 Jan 26

🔬 Science Biotechnology

Electroporation has a huge space of possible settings, so getting DNA into non-model microbes is often slow, hit-or-miss, and leaves researchers unsure why experiments fail.
A robotic electroporator that tests many buffers, voltages, waveforms, and plasmid origins—and uses a Bayesian optimizer to choose conditions—can rapidly find working protocols and massively improve transformation efficiency.
Scaling cultivation and transformation for diverse microbes will open up study and engineering of vast, untapped biological diversity, leading to new enzymes, tools, and biotech applications beyond standard lab organisms.

Bill Gates Launches Global Tracking Tattoos

2nd Smartest Guy in the World • 3577 implied HN points • 24 Jan 24

🏥 Health Politics Biotechnology

Bill Gates is involved in projects like global tracking tattoos and genetically modified mosquitoes.
There are concerns raised about Bill Gates funding schemes that involve cutting down forests and deploying GMO Frankenmosquitos.
There is skepticism and caution advised regarding Bill Gates' projects to control and monitor the population.

Science fictions are outpacing science facts for polygenic embryo selection

The Infinitesimal • 479 implied HN points • 13 Jul 24

🔬 Science Biotechnology

Polygenic embryo selection may not improve outcomes significantly for complex traits like IQ or education, as gains from such selections are often minimal.
Screening for diseases may also have limited results, especially when those diseases are defined by arbitrary thresholds rather than clear biological mechanisms.
There may be unintended consequences from embryo selection, such as increased risk for other traits, due to complex genetic correlations that are not fully understood.

Machine Learning-Assisted Directed Evolution with Bruce Wittmann

Lever • 19 implied HN points • 16 Oct 24

🔬 Science Biotechnology

Bruce Wittmann's journey in science started from pre-med and led him to research at notable institutes like Caltech.
He worked on machine learning to improve protein engineering, building tools that can help many people in the field.
His collaboration with renowned scientists and contributions to published research highlight the exciting potential in protein design and computational biology.

More Roche SBX Workflow Thoughts

ASeq Newsletter • 21 implied HN points • 05 Mar 26

🔬 Science Biotechnology

There are two Axelios workflows being compared: SBX-D is a duplex, multi-day protocol around 19 hours, while SBX-Fast completes in roughly 3.5 hours.
Collected run data were used to directly compare SBX-D and SBX-Fast to show their relative throughput and performance differences.
The comparison highlights trade-offs between speed and duplex capability, so choosing a workflow depends on whether higher throughput or shorter turnaround time is more important.

Cancer Science in On a Tear

Ground Truths • 7436 implied HN points • 10 Nov 24

🏥 Health & Wellness Biotechnology

Recent research has made great progress in understanding cancer, revealing that many cancer cells may come from multiple clones. This helps explain how cancer develops and spreads.
Studies are showing how powerful visual mapping of tumors can be, especially for identifying how different immune responses affect the growth of cancers like breast and ovarian cancer.
New insights into circular DNA in cancer cells are revealing its role in tumor growth and resistance to treatments. There is even potential for new therapies targeting this DNA to combat cancer.

A Few More Roche SBX Chip Notes

ASeq Newsletter • 21 implied HN points • 03 Mar 26

🔬 Science Biotechnology

More technical details and small updates about the Roche SBX chip are still being discussed.
TruPath is noted as interesting but not very exciting here, partly because it’s already been covered elsewhere.
The write-up is behind a paywall and requires a paid subscription or sign-in to access.

Why Engineer Biology?

Niko McCarty • 39 implied HN points • 10 Sep 24

🔬 Science Biotechnology

Cells can help solve big problems like hunger and climate change by using chemistry and physics to rearrange atoms into useful materials. They are like natural tools that can be engineered to do tasks we need.
Engineering biology has a successful history, like when Norman Borlaug improved wheat crops in Mexico. These achievements show that one innovative solution can make a huge difference over time.
Now is a great time to work in biotechnology because tools for studying and changing genes are getting cheaper and easier to use. This means more people, from different backgrounds, can contribute to solving biological challenges.

The Dawn of Spatial Medicine

Ground Truths • 5773 implied HN points • 26 Oct 24

🏥 Health & Wellness Biotechnology

Spatial medicine is a new field that combines biology and healthcare, focusing on using spatial data to improve patient treatment. This means doctors can analyze cells and tissues in detail to better understand diseases.
Recent research showed that a new treatment using JAK inhibitors was effective for patients with toxic epidermal necrolysis, a serious skin condition. This treatment worked quickly and with no side effects, showcasing the potential of spatial medicine.
The integration of AI and deep learning plays a key role in spatial medicine, helping to analyze complex data and improve patient outcomes. This advancement could lead to more personalized and effective treatments in the future.

🧬 RFK Jr.’s dumb war on mRNA vaccines and America’s medical future

Faster, Please! • 1096 implied HN points • 06 Aug 25

🏥 Health Politics Biotechnology

The U.S. is stepping back from mRNA vaccine development, which could harm future medical advancements. This shift may send a negative message about the country's commitment to science.
Robert F. Kennedy Jr. has canceled significant funding for mRNA research, which some scientists believe is important for fighting diseases like cancer. This decision is seen as anti-science by many.
With other countries like China investing heavily in biotechnological innovation, America risks losing its leadership in this crucial field. A retreat from science can lead to lost opportunities and lives.

Element High-throughput: Vitari

ASeq Newsletter • 29 implied HN points • 20 Feb 26

🔬 Science Biotechnology

A new high-throughput sequencer delivers up to 5 billion reads per flowcell, running 2x150bp in about 36 hours with a planned upgrade to 2x300bp in the future.
It targets a $100 per-genome consumable cost while the instrument is priced at $689,000, putting it cheaper per genome than some competitors but more expensive than others.
The system is compact (mini-fridge size) and uses two flowcells with six lanes each, positioning it as a solid alternative to existing high-throughput platforms.

Syndex Bio/Ultima

ASeq Newsletter • 21 implied HN points • 24 Feb 26

🔬 Science Biotechnology

Syndex Bio’s mcPCR can copy both DNA sequence and methylation marks during amplification, effectively enabling ‘PCR for methylation’. This should improve testing of small or non‑invasive oncology samples for earlier detection and recurrence monitoring.
Ultima Genomics launched a cheaper (~$850K) second instrument (ug200) that removes a separate ePCR step and doubles output per wafer, boosting throughput and lowering cost. It still appears bead‑based on unpatterned wafers, which suggests there’s further density headroom if they optimize wafer/flowcell design.
The bigger risk for Ultima is commercial: they need to find enough customers to absorb the massive throughput and drive the hyper‑elastic growth required for the business to survive. Capacity and performance may be strong, but market adoption is the key bottleneck.

DNA And Protein Sequencing Companies

ASeq Newsletter • 58 implied HN points • 02 Feb 26

🔬 Science Biotechnology

Protein sequencing is becoming a growing startup space, with many companies now working to make protein readouts practical.
Two main technical routes dominate—optical methods and nanopore-based sequencing—while a smaller set of firms pursue other novel approaches, and multiple companies are active in each category.
An updated directory of DNA sequencing companies is maintained, and contributors are invited to share additional firms to keep the list current.

Why Are We So Excited About Roche?

ASeq Newsletter • 21 implied HN points • 23 Feb 26

🔬 Science Biotechnology

Roche’s new Axelios single-molecule sequencer appears to be a real engineering breakthrough that can match or beat Illumina on key metrics like read length, speed, throughput, and accuracy.
Because Roche is large, well-funded, and running global pilots, it can aggressively compete on price and scale, potentially grabbing significant market share if reuse and pricing work out.
Significant uncertainty remains due to Roche’s mixed history, pricing and purchasing-cycle risks, and execution challenges, so excellent technology doesn’t guarantee immediate market disruption.

Can qPCR differentiate Vax Spike from C19 Spike

Nepetalactone Newsletter • 1729 implied HN points • 02 Aug 23

🔬 Science Biotechnology

qPCR cannot differentiate between Vax Spike and COVID Spike at protein level
Vaccine Spike DNA sequences are substantially different from Virus Spike
Use qPCR assays with specific markers to differentiate vaccine types in tissues

Weekly Dose of Optimism #174

Not Boring by Packy McCormick • 130 implied HN points • 19 Dec 25

🔬 Science Biotechnology

Science is developing organ perfusion systems that can keep organs alive outside the body for much longer, which could turn transplants into scheduled procedures, increase usable donations, and enable organ banking or swapping.
Self-experiments with high-dose psilocybin showed rapid improvements in mental health, brain plasticity, metabolic control, and inflammation. These results suggest psychedelics might become part of longevity strategies for some people, though risks remain.
Researchers are 3D-printing tiny helix structures that manipulate terahertz waves, unlocking a hard-to-reach part of the electromagnetic spectrum for telecom, sensing, and even polarization-encoded data. A year-end scientific review also highlights wide-ranging, high-impact advances across many fields, signaling rapid progress.

The Race to Make Designer Babies

Common Sense with Bari Weiss • 635 implied HN points • 11 Aug 25

🔬 Science Biotechnology

CRISPR-Cas9 technology can potentially eliminate genetic diseases, but it also raises ethical concerns about creating 'designer babies.'
Two individuals, He Jiankui and Cathy Tie, are in competition to lead the gene editing field in the U.S., each with different visions.
As gene editing technology advances rapidly, society must decide the ethical boundaries of its use before it's too late.